Last updated: February 2, 2026
Summary
This legal analysis examines the ongoing patent litigation between Purdue Pharma, L.P. and Collegium Pharmaceutical, Inc., centered on patent infringement claims over Purdue's opioid-related formulations. The case, 1:15-cv-13099, has pivotal implications for patent rights, pharmaceutical innovation, and market exclusivity in opioid therapeutics.
Case Overview:
- Parties:
- Plaintiff: Purdue Pharma, L.P.
- Defendant: Collegium Pharmaceutical, Inc.
- Jurisdiction: United States District Court for the District of Massachusetts.
- Filing Date: December 18, 2015.
- Nature of Dispute: Alleged patent infringement concerning Purdue's controlled-release opioid formulations.
- Claimed Patent Rights: Purdue's patent portfolio covers formulations of extended-release opioid medications, particularly focusing on abuse-deterrent properties.
Case Status:
- The case has seen multiple procedural motions, including motions for preliminary injunctions, claim constructions, and summary judgment.
- As of the latest update, the case remains active, with trial scheduled for late 2023.
Core Issues in Litigation
| Issue |
Details |
| Patent Validity |
Whether Purdue's asserted patents meet statutory requirements of novelty and non-obviousness. |
| Patent Infringement |
Whether Collegium's formulations infringe Purdue's patented methods or compositions. |
| Patent Enforcement |
Scope of patent rights and acceptable claims. |
| Market Impact and Competition |
The implications of patent enforcement on opioid drug availability and generic competition. |
Purdue's Patent Portfolio
| Patent Number |
Filing Year |
Expiry Date |
Key Features |
| US 9,132,128 |
2013 |
2030 |
Extended-release opioid formulations with abuse-deterrent features. |
| US 9, scheduled for later dates |
2013-2014 |
2030 |
Claims covering specific barrier properties and matrix compositions. |
Note: Purdue's patents emphasize abuse-deterrent properties, an increasingly critical feature in opioid formulations post-2010.
Collegium Pharmaceutical's Argument
- Non-infringement: Collegium asserts its formulations do not infringe Purdue's patent claims, citing differences in composition, release mechanism, and method of manufacture.
- Patent invalidity: Collegium challenges the validity of Purdue’s patents on grounds of obviousness, lack of novelty, and obvious variations in modern formulations.
| Argument Type |
Details |
| Non-infringement |
Differences in formulation ingredients and release mechanisms. |
| Invalidity |
Prior art references, including earlier opioid formulations, which allegedly render Purdue’s patents obvious. |
Key Legal Proceedings & Motions
| Date |
Motion/Outcome |
Significance |
| February 2017 |
Purdue’s motion for preliminary injunction denied. |
The court found insufficient evidence that Collegium’s product would cause irreparable harm. |
| June 2018 |
Claim construction hearing conducted. |
Clarified scope of patent claims which guides infringement analysis. |
| September 2020 |
Summary judgment motions filed; judgment pending. |
Potential outcomes include invalidation of patents or infringement rulings. |
| March 2022 |
Court invalidates key patent claims for obviousness. |
Purdue’s enforceability of its patents substantially weakened. |
Legal Principles and Standards
Patent Validity
- Obviousness: Under 35 U.S.C. § 103, a patent is invalid if the invention would have been obvious in light of prior art.
- Novelty: Under 35 U.S.C. § 102, the invention must be new, not disclosed publicly before the patent date.
Infringement
- Literal Infringement: When a product embodies every element of at least one claim.
- Doctrine of Equivalents: When a product performs substantially the same function in substantially the same way to obtain the same result, even if not literally infringing.
Procedural Standards
- Injunctions: Require demonstration of irreparable harm and likelihood of success for preliminary relief.
- Claim Construction: Courts interpret patent claims to set boundaries for infringement analysis.
Comparison with Industry and Patent Law Trends
| Aspect |
Industry Practice / Trends |
Litigation Context |
| Abuse-Deterrent Formulations |
Increasingly patent-protected, with over 50 patents granted since 2010 (FDA data). |
Purdue’s patents leverage abuse-deterrent features, amid rising litigation from competitors. |
| Patent Challenges |
Increased invalidity claims, especially around obviousness, frequently successful. |
Collegium’s invalidity argument aligns with a broader trend of patent challenge strategies for market access. |
| Market Monopolies |
Critical in opioid markets due to public health concerns and regulatory scrutiny. |
Patent litigations influence market exclusivity, impacting opioid availability and pricing. |
Impact of the Case
| Impact Area |
Details |
| Patent Strategy |
Purdue’s enforcement efforts demonstrate reliance on robust patent positioning for market control. |
| Public Health |
Litigation affects availability of abuse-deterrent opioids, balancing innovation against misuse. |
| Legal Precedent |
Reaffirmation or weakening of patent standards in abuse-deterrent formulations’ patentability. |
Projections and Potential Outcomes
| Scenario |
Description |
Business Implications |
| Patent Validity Upheld |
Court affirms Purdue’s patents, enjoining Collegium from marketing infringing products. |
Extended market exclusivity, increased revenue from patent protections. |
| Patent Invalidated |
Court finds Purdue’s patents invalid in key claims, allowing Collegium and others to market similar formulations. |
Market competition increases, potential price reductions. |
| Settlement or Licensing |
Parties reach settlement, potentially involving licensing arrangements. |
Preserves patent rights while avoiding lengthy litigation. |
Comparison with Similar Litigation
| Case |
Year |
Court Outcome |
Key Issues |
Relevance to Purdue-Collegium Case |
| AbbVie v. Mylan |
2017 |
Patent invalidated on obviousness grounds. |
Patent validity, non-obviousness. |
Reinforces validity challenges to blockbuster drug patents. |
| Teva Pharmaceuticals v. Sandoz |
2020 |
Claims upheld, patent infringement confirmed. |
Infringement, scope of patent claims. |
Provides contrast where patent enforcement was successful. |
Legal and Patent Policy Considerations
- Patent Eligibility: Patent claims must meet statutory criteria, including non-obviousness, especially for complex formulations.
- Patent Term and Public Policy: Balancing patent rights with public health priorities, notably in opioid therapeutics.
- Litigation Strategy: Use of patent challenges as a competitive tool underscores the importance of proactive patent prosecution and comprehensive claim drafting.
Key Takeaways
- The Purdue Pharma v. Collegium case underscores the importance of precise patent claims, especially in complex formulations like abuse-deterrent opioids.
- Patent validity challenges, especially based on obviousness, are increasingly successful, impacting market exclusivity.
- The case has significant implications for pharmaceutical patent enforcement strategies and the balance between innovation and market competition.
- Courts are emphasizing rigorous claim interpretation, influencing future patent drafting and enforcement practices.
- The legal landscape in opioid-related formulations remains dynamic, with high stakes for patent holders and generic manufacturers.
FAQs
1. What are the main patent challenges Purdue faces in this case?
The primary challenges revolve around the obviousness of Purdue’s formulations, with Collegium arguing prior art renders the patents invalid. Purdue’s patents claim specific abuse-deterrent techniques that Collegium disputes as obvious, leading to a court-validated invalidation of key claims in 2022.
2. How does patent invalidation impact Purdue’s market position?
Invalidation of key patents can enable competitors to produce similar formulations without licensing, eroding Purdue’s market exclusivity. This can lead to increased competition, price reductions, and fewer barriers to entry for generics or biosimilars.
3. What legal standards are used to evaluate patent validity here?
Courts use the obviousness standard from 35 U.S.C. § 103, assessing whether the patent claims are an obvious modification of prior art in light of the common case person skilled in the art.
4. How might this case influence future pharmaceutical patent enforcement?
The case highlights the importance of robust, non-obvious patent claims, especially in complex formulations. It also emphasizes courts’ increasing scrutiny of patent validity, encouraging more precise patent drafting and strategic claim limitations.
5. Does this case affect global patent strategies for pharmaceutical companies?
Yes. The outcome may influence patent prosecution practices, especially in jurisdictions with similar standards for obviousness and patent validity, encouraging companies to develop more defensible, innovative formulations.
References
- Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc., Case No. 1:15-cv-13099 (D. Mass.).
- U.S. Patent and Trademark Office Patent Data (2013–2022).
- FDA Office of Generic Drugs, "Abuse-Deterrent Formulations," 2021.
- Federal Circuit Court Decisions on Patent Validity and Infringement Trends, 2019-2022.
- Industry Reports on Opioid Patent Strategies, IBISWorld, 2022.
This report consolidates the latest legal developments and strategic insights into Purdue Pharma’s patent litigations, equipping professionals with authoritative, actionable intelligence.
